JW (Cayman) Therapeutics Co. Ltd. · HKEX:2126

JW (Cayman) Therapeutics — JW Therapeutics — H1 2023 Earnings Presentation

22 slides from JW (Cayman) Therapeutics's earnings presentation, Sep 11, 2023

  1. Slide 1: 2023 Interim Results Presentation

    JW Therapeutics (2126.HK) 2023 Interim Results Presentation

  2. Slide 2: Disclaimer

    Disclaimer 免责声明 This presentation may contain forward-looking, confidential and/or proprietary information including without limitation to JW Therapeutics’ manufacturing process, pipeline, business development and third party collaboration, etc, which are provided on as-is basis, and/or based on man

  3. Slide 3: 2023 1H: Comprehensive Enhancement of Operational Efficiency to Accelerate Commercialization and Pipeline Development

    2023 1H: Comprehensive Enhancement of Operational Efficiency to Accelerate Commercialization and Pipeline Development Financial Update  2023 1H revenue reached RMB 87.7 million, representing an increase of 32.9% YoY.  Gross profit reached RMB 44.8 million, representing an increase of 93.9% YoY. 

  4. Slide 4: Carteyva to Sustain Strong Growth with Promising Untapped Market Potential

    Carteyva® to Sustain Strong Growth with Promising Untapped Market Potential Untapped Market Potential for Cell Immunotherapy Continuously Drive Operational Excellence 30K 2% 32.9% 28.7% r/r B-NHL patients in China1 Receiving CAR-T treatment2 Revenue YoY Growth Selling Expense Best in Class Efficacy

  5. Slide 5: JW's R&D Strategies

    JW’s R&D Strategies Expand Relma-cel Use in Heme Indications With successful approvals in LBCL & FL, Pursue 2L & 1L LBCL, MCL & pALL Expand Relma-cel Indications into Autoimmune Diseases With Relma-cel’s safety profile and potency, develop CAR-T for the high unmet needs in moderate and severe SLE Ad

  6. Slide 6: Our Hematology Pipeline: Expanding Indications to Benefit Patients

    Our Hematology Pipeline: Expanding Indications to Benefit Patients Hematologic Malignancies and Autoimmune Diseases Pivotal / Product Target Indication Commercial Rights Pre-clinical Phase I Phase II/III NDA Marketed Partner Mainland China, Hong Kong, 3L LBCL Macau* Mainland China, Hong Kong, 3L FL

  7. Slide 7: Carteyva: Approved for 2 Indications to Meet the Needs of NHL Patients

    Carteyva®: Approved for 2 Indications to Meet the Needs of NHL Patients A Competitive Profile today, and competitive for the future 3L LBCL Approved in 2021 Comparable Efficacy1 Superior Safety Profile1 Excellent long-term efficacy: 2Y OS 69.3% * Not from a head-to-head comparison study * Not from a

  8. Slide 8: The Changing Landscape in LBCL: Use of CAR-T in Earlier Lines of Therapy

    The Changing Landscape in LBCL: Use of CAR-T to Address the Unmet Medical Need in Earlier Lines of Therapy CAR-T Opportunities in Frontline and 2nd Line Treatment, but Safety Profile Matters Newly Diagnosed LBCL FRONTLINE THERAPY ~90% R-CHOP x 6-8 cycles  Many Don’t Benefit from REFRACTORY or RELAP

  9. Slide 9: Carteyva Development in Early Line Treatment of LBCL

    Carteyva® Development in Early Line Treatment of LBCL Carteyva® in 2nd Line LBCL – Study 003 – poor risk primary refractory disease  12 patients with poor risk disease, including: • extranodal disease [33%] Response Rate 12 mo OS CRS sCRS ICANS Severe ICANS • high International Prognostic Index [75

  10. Slide 10: Carteyva: Advancing in CD19+ Indications: MCL

    Carteyva®: Advancing in CD19+ Indications: MCL • Carteyva® was granted Breakthrough Therapy Designation in patients with MCL by NMPA • Historically, standard therapy has provided brief responses or no response MCL • Evaluating very poor risk MCL patients; those who failed of stopped BTK inhibitors •

  11. Slide 11: Significant Unmet Need in Lupus: An Opportunity for Relma-cel

    Significant Unmet Need in Lupus: An Opportunity for Relma-cel -Conventional Treatments are Inadequate & Organ Damage Continues Over Time Large Need: SLE Disease Impacts to Health & Survival SLE has few disease modifying therapies Needed for long-term organ preservation Measurable Therapy Goal: Disea

  12. Slide 12: First in Human Study of Relma-cel in SLE

    First in Human Study of Relma-cel in SLE First in Human study kick off from 1Q 2023 and actively enrolling, promising efficacy and Safety data received from initial dose level Target Population Patients with moderate-to-severe, refractory/relapse Systemic Lupus Erythematosus (SLE) SLE Classification

  13. Slide 13: Very Promising Efficacy and Safety Signal from IIT Study

    Very Promising Efficacy and Safety Signal from IIT Study Temperature℃ Blood Test Blood Test 38.4 White blood Cell(3.5-9.5) Neutrophils(1.8-6.3) Lymphocyte(1.1-3.2) Hemoglobin(115-150) Platelet(125-350) 38.2 7 250 38 6 37.8 200 5 37.6 4 150 37.4 3 37.2 100 37 2 50 36.8 1 36.6 0 0 D7 D8 D9 D10 D11 bas

  14. Slide 14: Our Pipeline Beyond Heme: Expanding Solid Tumor Indications

    Our Pipeline Beyond Heme: Expanding Solid Tumor Indications High Incidence Diseases in China: HCC, Lung Cancer and more Pivotal / Product Target Indication Commercial Rights Pre-clinical Phase I Phase II/III NDA Marketed Partner Mainland China, Hong Kong, JWATM204 1 GPC3 HCC Macau, Taiwan , and memb

  15. Slide 15: JWATM204 & 214: GPC3 CAR-T in HCC

    JWATM204 & 214: GPC3 CAR-T in HCC Need: ~400K HCC cases newly diagnosed in China annually • ~80% pts are initially-diagnosed as advanced/metastatic stage [unresectable] disease • HCC has poor prognosis (5-ys OS rate ~12%) with currently available therapies Target Potential: Cell surface expression o

  16. Slide 16: JWTCR001: MAGE-A4 Autologous TCR-T in Multiple Solid Tumors

    JWTCR001: MAGE-A4 Autologous TCR-T in Multiple Solid Tumors JW’s TCR-T Product Candidate Employing Novel Technology & Successful Manufacturing Processes TCR-T has Solid Proof of Concept Through Clinical Trials Novel Technology Licensed from 2seventy Bio Phase 2: NY-ESO-1/HLA-A2(GSK) & MAGE-A4/HLA-A2

  17. Slide 17: JWCAR031: DLL3 CAR-T in SCLC

    JWCAR031: DLL3 CAR-T in SCLC Need: ~80K SCLC cases newly diagnosed in China annually • ES-SCLC accounts for ~70% SCLC • 2nd Line therapy in ES-SCLC has mOS<6m (ORR~15%) Target Potential: Cell surface expression of DLL3 in 72% SCLC • ~85% SCLC expressed positive DLL-3 POC: Tarlatamab, a T cell engage

  18. Slide 18: Progress of Solid Tumor Projects

    Progress of Solid Tumor Projects 01 02 03 JWATM 204 & 214 JWTCR001 JWCAR031 (GPC3 CAR-T) (MAGE-A4 TCR-T) (DLL3 CAR-T) • Both studies in HCC are actively • Process development is ongoing • Process development is ongoing enrolling and preliminary result received • Study Site is in preparation • Dose e

  19. Slide 19: In-house Generated New Pipeline with Global Reach

    In-house Generated New Pipeline with Global Reach New Autologous CAR Pipeline Autologous Therapies • Proven approach • Leveraging on JW infrastructure and experience Global Next-Gen New Pipeline Value Drivers Armored Commercial Manufacturing • Targeting unmet needs in China with potential global Rig

  20. Slide 20: Key Financial Update

    Key Financial Update Revenue Gross Margin (RMB million) (RMB million) +93.9% +32.9% 50 40 30 44.8 87.7 20 23.1 GM% 51.1% 66.0 10 GM% 35.0% 0 1H 2022 1H 2023 1H 2022 1H 2023 RMB 87.7M 2023 1H total revenue 30% Cost Reduction per unit from 2021 to 1H 2023 2023 1H revenue increase supported by 2023 1H

  21. Slide 21: Key Financial Update

    Key Financial Update Operating expenses Loss for the period Cash balance * • Stringent control on G&A expenses • Loss for the period narrowed down due to higher gross Net cash outflow decreased primarily due to: • 2023 1H R&D expenses is slightly higher than 2022 1H, profit and less operating expens

  22. Slide 22: Thank You!

    THANK YOU!

JW Therapeutics — H1 2023 Earnings Presentation on 6ix